Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 223.33% from the company’s previous close.
INZY has been the topic of a number of other reports. Wedbush restated an “outperform” rating and issued a $15.00 price target on shares of Inozyme Pharma in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Tuesday. Finally, Wells Fargo & Company initiated coverage on shares of Inozyme Pharma in a report on Thursday, May 30th. They issued an “overweight” rating and a $14.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $16.00.
Get Our Latest Stock Analysis on Inozyme Pharma
Inozyme Pharma Price Performance
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). Analysts expect that Inozyme Pharma will post -1.59 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new position in shares of Inozyme Pharma in the 2nd quarter worth approximately $68,000. Values First Advisors Inc. acquired a new position in shares of Inozyme Pharma in the 2nd quarter worth approximately $76,000. SG Americas Securities LLC lifted its position in shares of Inozyme Pharma by 46.9% in the 4th quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock worth $90,000 after purchasing an additional 6,784 shares during the period. American Century Companies Inc. lifted its position in shares of Inozyme Pharma by 11.0% in the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after purchasing an additional 5,673 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Inozyme Pharma by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after purchasing an additional 13,867 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.
Inozyme Pharma Company Profile
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Recommended Stories
- Five stocks we like better than Inozyme Pharma
- Want to Profit on the Downtrend? Downtrends, Explained.
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- How to buy stock: A step-by-step guide for beginnersÂ
- MarketBeat Week in Review – 8/5 – 8/9
- Stock Dividend Cuts Happen Are You Ready?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.